Wolfgang Miesbach Explores the DosEmi Study’s Interim Results on Emicizumab
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:
”Cost-Effective Care Without Compromising Safety in Haemophilia!
The Dutch DosEmi study’s interim results demonstrate that reducing emicizumab doses by 39% maintains comparable bleeding control to conventional dosing.
The Challenge
Emicizumab has transformed haemophilia A management since its 2019 approval, offering subcutaneous administration and longer dosing intervals.
However, its high cost creates significant barriers to access, particularly in resource-limited settings.
Current label dosing results in plasma concentrations averaging 55 µg/mL, yet pharmacodynamic analyses suggest effectiveness at lower levels
The New Idea
This multicenter Dutch trial employed pharmacokinetic-guided dosing targeting trough concentrations of 30±5 µg/mL instead of the conventional 45 µg/mL.
Using validated PK modeling and Bayesian analysis, researchers provided personalized dosing recommendations through an online platform.
The Results
Among 26 adults with severe hemophilia A followed for six months:
- 69% remained bleed-free on conventional dosing vs. 58% on reduced dosing (statistically comparable)
- Joint bleed protection remained stable: 85% vs. 88% without joint bleeds
- Annualized bleeding rate stayed low: 0.7 vs. 0.9 bleeds/year
- Only one spontaneous muscle bleed occurred (at adequate drug levels)
Importantly, participants extended their dosing intervals from weekly/biweekly to biweekly/monthly injections—potentially reducing treatment burden, especially for children who experience injection-site pain.
The Clinical Impact
This is the first prospective crossover study validating PK-guided dose reduction in haemophilia A.
Unlike retrospective studies from lower-income countries showing effectiveness at ultra-low doses, this research was conducted in participants already on conventional prophylaxis with established bleeding control—making the findings directly applicable to clinical practice in high-income settings.
The study met all pre-specified safety criteria and has now expanded to include participants under 16 years.
Final results expected in 2027 could establish new treatment guidelines, making emicizumab accessible to more patients globally while maintaining the excellent safety profile that has made it a game-changer in hemophilia care.
As healthcare systems worldwide face increasing cost pressures, this research demonstrates that personalized, data-driven medicine can simultaneously improve patient outcomes and resource utilization.”
Read the full article in JTH.
Article: Pharmacokinetic-guided dose reduction of emicizumab in congenital hemophilia A: Interim Analysis of the DosEmi Study
Authors: Konrad van der Zwet, Amber D.W. de Vos, Marjon H. Cnossen, Floor C.J.I. Heubel-Moenen, Saskia E.M. Schols, Paula F. Ypma, Paul L. den Exter, Hélène L. Hooimeijer, Michiel Coppens, Ron A.A. Mathôt, Alexander Janssen, Anouk A.M.T. Donners, Ilmar Kruis, Rolf T. Urbanus, Lize F.D. van Vulpen, Corien L. Eckhardt, Roger E.G. Schutgens, Kathelijn Fischer on behalf of OPTI-CLOT Study Group and SYMPHONY Consortium
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 6, 2026, 16:39Dhinesh Selvaraju: FDA Approves Narsoplimab (Yartemlea) as 1st Treatment for TA-TMA in Adults and Children
-
Apr 6, 2026, 16:38Linda Vorberg: A Detailed Analysis on The Usefulnessof CT for DL-Based Stroke Lesion Segmentation
-
Apr 6, 2026, 16:37Colleen Hearn: Telestroke Helps Resource-Limited Facilities Gain Access to Unavailable Expertise
-
Apr 6, 2026, 16:37Nicolas Hubacz: AI Maps Neuroplasticity in Stroke Recovery – How the Brain Adapts After Injury
-
Apr 6, 2026, 16:36Cristina de Diego Alonso: Movement Is Not Just an Exercise, It Is The Rhythm of Daily Life
-
Apr 6, 2026, 16:35Charles Okyere Boadu: What Is The Most Likely Cause of Persistent Thrombocytopenia Despite Transfusion?
-
Apr 6, 2026, 16:34Tumor Mutations and VTE Risk – New Insights from a 12,500-Patient Cancer Study – JTH
-
Apr 6, 2026, 16:31Wolfgang Miesbach: New Real-World Data Reveal Ongoing Burden in Moderate-to-Severe Haemophilia A
-
Apr 6, 2026, 16:26Heghine Khachatryan։ Targeting High Risk Antiphospholipid Syndrome in Pregnancy with Hydroxychloroquine